The policy change in Tdap, the tetanus, diphtheria, acellular pertussis vaccine, comes on the heels of pertussis outbreaks across the United States. The new recommendation is to vaccinate pregnant women in each and every pregnancy in the third trimester, preferably between 27 and 36 weeks. This includes pregnant women who have been vaccinated previously. Tdap is FDA approved for adults as single use only, so repeat maternal vaccination is an off-label use. Tdap booster is recommended universally for all adults, including those aged 65 years and older.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2013-01-30 12:38:462013-05-27 10:02:01Novedades en vacunas. United States, 2013
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for Bexsero, a new vaccine intended for the immunisation of individuals over two months of age against invasive meningococcal disease caused by Neisseria meningitis group B.
There is currentlyno authorised vaccine available in the European Union (EU) for bacterial meningitis caused by Neisseria meningitis group B.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2012-11-20 11:09:562013-07-16 10:54:14European Medicines Agency recommends approval of first vaccine for meningitis B
On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants. PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23, Merck & Co. Inc.), the vaccine currently recommended for these groups of adults. The evidence for the benefits and risk of PCV13 vaccination of adults with immunocompromising conditions was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and designated as a Category A recommendation (2,3). This report outlines the new ACIP recommendations for PCV13 use; explains the recommendations for the use of PCV13 and PPSV23 among adults with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants; and summarizes the evidence considered by ACIP to make its recommendations.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2012-10-17 08:15:292013-07-16 10:57:50MMWR: Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Documento de consenso de las Sociedades Científicas de Medicina Preventiva: Sociedad Española de Medicina Preventiva, viagra 100mg Salud Pública e Higiene; Sociedad Gallega de Medicina Preventiva; Societat Valenciana de Medicina Preventiva i Salut Pública; Sociedad Norte de Medicina Preventiva y Salud Pública; Sociedad Canaria de Medicina Preventiva Hospitalaria; Sociedad Andaluza de Medicina Preventiva; Sociedad Madrileña de Medicina Preventiva; Sociedad Castellano Manchega de Medicina Preventiva y Salud Pública. Con la colaboración del CNM-ISCIII.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2012-10-04 11:13:092016-01-26 11:13:42Recomendaciones de Vacunación Antineumocócica en el Adulto por Indicación Médica
El personal sanitario se encuentra incluido cada año entre los grupos de riesgo con indicación para vacunarse frente a la gripe. No obstante, las coberturas vacunales entre el personal sanitario en nuestro país son muy bajas no superando el 25%. Convencidos de que una de las mejores herramientas para aumentar estas coberturas entre los profesionales de nuestro país son las evidencias científicas, 19 Sociedades Científicas y Asociaciones Profesionales que agrupan a los profesionales sanitarios más directamente relacionados con la gripe como problema de salud, así como el Consejo General de Enfermería, se han reunido para debatir y elaborar este documento de consenso con el objetivo de concienciar al personal sanitario sobre la conveniencia de su vacunación frente a la gripe y de los beneficios que de ella se derivan para sí mismos, para sus pacientes y para el resto de la población. Esta recomendación está basada en 3 pilares básicos: argumento de necesidad, de ética y de ejemplaridad.
http://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.png00Socinortehttp://www.socinorte.com/wp-content/uploads/2016/02/LogoCabecera.pngSocinorte2012-09-25 11:15:122013-07-16 10:59:35Consenso sobre la vacunación frente a la gripe en el personal sanitario
Utilizamos cookies propias y de terceros para mejorar nuestro servicio y mostrar contenido relacionado con tus preferencias mediante el análisis de los hábitos de navegación.<br /> Si continúas navegando, consideramos que aceptas su uso. Más información
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
